Simple Summary Neoadjuvant therapy, used before surgery, is an important part of breast
cancer treatment. Not only can it shrink tumors, but it can also provide valuable information …

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are frequently
associated with immune-related adverse events (irAEs). This article offers a novel synthesis …

The number of patients with cancer qualifying for treatment with immune checkpoint
inhibitors (ICIs) continues to increase, and a clearer understanding of the mechanisms …

The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse
events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein …

Circulating tumor DNA (ctDNA) represents a powerful measure of minimal residual disease
(MRD) in colorectal cancer (CRC). Although immunotherapy has been widely established in …

Resistance to immunotherapy in bladder cancer has greatly limited its clinical application.
Through single-cell sequencing, we determined that ACSM6, an oncogene that is highly …

Immune checkpoint inhibitors (ICIs) related myocarditis is a rare complication of modern
immunotherapy. It can present as an asymptomatic subclinical condition or full-blown …

We read with interest the correspondence by Guven 1 regarding our manuscript 2 in which
we reported that higher corticosteroid peak dose to treat immune-related adverse events …

Immune checkpoint inhibitors (ICIs) have significantly changed cancer therapy, improving
patient survival rates and clinical outcomes. Nevertheless, the use of PD-1/PD-L1 inhibitors …

Abstract Aim Durvalumab plus tremelimumab (Dur/Tre) is a first‐line systemic treatment
option for unresectable hepatocellular carcinoma (uHCC). However, the management of …